Try Calculator
← Back to Compound Library NOOTROPICS

Dihexa

Introduction and Overview

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide), also known by its developmental code name PNB-0408, is a small synthetic oligopeptide derived from angiotensin IV that represents a novel approach to cognitive repair and neuroprotection. Unlike traditional nootropics that primarily stimulate neurotransmitter activity, Dihexa is investigated for its potential ability to influence the structural connectivity of the brain itself—specifically how neurons form and strengthen synaptic connections. Developed at Washington State University by Dr. Joseph Harding and colleagues over nearly two decades of research, Dihexa gained attention in preclinical studies for its unusually potent effects on synaptogenesis, the process by which new synapses are formed between neurons. In cell culture assays of new neuronal connections, Dihexa was described as being seven orders of magnitude (10 million times) more potent than brain-derived neurotrophic factor (BDNF)—an important distinction, since BDNF itself has poor pharmacological usability due to its inability to cross the blood-brain barrier. Dihexa readily crosses the blood-brain barrier, exhibits exceptional metabolic stability with a half-life of approximately 12 to 13 days, and has demonstrated oral bioavailability in animal models. The compound works primarily through activation of the hepatocyte growth factor (HGF)/c-Met receptor signaling pathway, promoting dendritic spine formation, synaptogenesis, and neuroprotection. An improved pharmaceutical analog called fosgonimeton (ATH-1017) completed several Phase 2 clinical trials for Alzheimer’s disease and Parkinson’s disease dementia before development was discontinued in 2024. Dihexa is best understood as a cognitive repair research peptide, not a stimulant or casual nootropic. Its unique value lies in its potential ability to influence how the brain rebuilds connections rather than simply increasing alertness or neurotransmitter activity.

Quick Reference

Property Detail Chemical Name N-hexanoic-Tyr-Ile-(6) aminohexanoic amide (N-Hexanoyl- L-tyrosyl-N-(6-amino-6-oxohexyl)-L-isoleucinamide) Code Name PNB-0408 Drug Class Angiotensin IV-derived oligopeptide; HGF/c-Met pathway modulator Molecular Formula C₂₇H₄₄N₄O₅ Molecular Weight 504.7 g/mol CAS Number 1401708-83-5 Half-Life Approximately 12–13 days Routes of Administration Oral, transdermal, subcutaneous injection Primary Target Hepatocyte growth factor (HGF)/c-Met receptor system HGF Binding Affinity Kd = 65 picomolar (pM) BBB Penetration Excellent; readily crosses blood-brain barrier Development Status Research chemical; fosgonimeton (ATH-1017) analog discontinued after Phase 2/3

How It Works

Hepatocyte Growth Factor (HGF) Activation

Dihexa’s primary mechanism of action involves binding to and potentiating hepatocyte growth factor (HGF), a naturally occurring protein that plays a critical role in neuronal survival, synaptic formation, and tissue repair following injury. Dihexa binds to HGF with exceptionally high affinity (Kd = 65 picomolar) and induces HGF dimerization, creating a functional ligand that activates the c-Met receptor on neurons. The c-Met receptor is a receptor tyrosine kinase that, when activated by HGF, triggers intracellular signaling cascades including the PI3K/AKT and MAPK pathways. These cascades promote neuronal protection, cell survival, cell migration, and—most importantly for cognitive function—synapse formation. The HGF/c-Met system is critical for neural development and repair, and its activation by Dihexa represents a fundamentally different approach to cognitive enhancement than neurotransmitter-based strategies. Research by Benoist et al. (2014) confirmed that Dihexa’s procognitive effects are entirely dependent on the HGF/c-Met system. When an HGF antagonist (“Hinge”) was delivered intracerebroventricularly, it completely blocked the cognitive-enhancing effects of orally administered Dihexa, confirming the pathway specificity. Notably, the HGF antagonist alone had no effect on normal cognitive performance, suggesting the HGF/c-Met system is primarily engaged during injury or deficit states rather than normal learning.

Synaptogenesis and Dendritic Spine Formation

Dihexa’s most remarkable property is its ability to promote synaptogenesis—the formation of new functional synaptic connections between neurons. In cell culture assays, Dihexa induced the growth of dendritic spines on hippocampal neurons and facilitated the formation of new synapses. These were demonstrated to be functional synapses, not merely structural changes. In neurotrophic activity assays, Dihexa was found to be seven orders of magnitude (10 million times) more potent than BDNF at promoting new neuronal connections. While BDNF is considered the gold standard compound for creating neuronal connections, its poor pharmacological properties (inability to cross the blood-brain barrier, rapid degradation) limit its

therapeutic utility. Dihexa overcomes these limitations while producing effects through the HGF/c-Met pathway rather than the BDNF/TrkB pathway.

Blood-Brain Barrier Penetration and Metabolic Stability

A critical advantage of Dihexa over its parent compound angiotensin IV is its ability to efficiently cross the blood-brain barrier. Angiotensin IV itself demonstrated procognitive effects but was highly susceptible to degradation by proteolytic enzymes, severely limiting its pharmaceutical utility. Dihexa was specifically engineered with metabolic stabilization modifications (N-hexanoic acid cap and C-terminal aminohexanoic amide) that confer resistance to enzymatic degradation while maintaining blood-brain barrier permeability. The resulting compound has a half-life of approximately 12 to 13 days, producing long-lasting signaling effects well beyond its presence in circulation. This extended duration of action is one reason experienced researchers favor low, infrequent dosing rather than continuous daily exposure.

Context-Dependent Effects

An important characteristic of Dihexa’s mechanism is its apparent context dependence. The HGF/c-Met system appears to be primarily engaged during conditions of neural injury or deficit rather than during normal cognitive function. This means Dihexa’s effects are most likely when the brain is actively engaged in learning, recovery, or repair—not when it is passively stimulated. This has significant implications for dosing strategy and expectations, as the compound is not simply a “smart pill” but rather a facilitator of neural repair and plasticity.

Benefits

Cognitive Repair and Neurodegeneration Research

Dihexa has been investigated in preclinical models of cognitive impairment and neurodegeneration:

Unlike drugs that attempt to slow neuronal loss, Dihexa is studied for its potential to restore lost connectivity—not merely preserve existing function. This represents a fundamentally different therapeutic approach to neurodegenerative disease.

Learning, Memory, and Neuroplasticity

Because Dihexa promotes synapse formation, it has attracted interest for applications related to memory consolidation, learning speed and retention, and neural adaptability during rehabilitation or retraining. Importantly, reported effects appear to be context-dependent, meaning benefits are most likely when the brain is actively engaged in learning or recovery.

Long Signaling Duration

Dihexa demonstrates a long functional signaling window in preclinical data, with effects persisting well beyond its presence in circulation due to its 12- to 13-day half-life and the structural nature of synaptic changes (once formed, new synapses persist). This property allows for lower-frequency dosing protocols compared to conventional nootropics.

Neuroprotection

Through activation of the HGF/c-Met pathway and its downstream PI3K/AKT signaling cascade, Dihexa provides neuroprotective effects that support neuronal survival under stress conditions. Preclinical evidence also suggests protective effects against aminoglycoside-induced ototoxicity (hearing cell damage) through an HGF-dependent mechanism.

Fosgonimeton (ATH-1017) Clinical Development

While Dihexa itself has not undergone formal human clinical trials, its pharmaceutical analog fosgonimeton (ATH-1017) completed several Phase 2 trials:

ADAS-Cog11 cognitive scale in mild-to-moderate Alzheimer’s patients not taking acetylcholinesterase inhibitors.

improvement in Parkinson’s disease dementia and dementia with Lewy bodies.

biomarker improvements. Development was subsequently discontinued.

What the Science Shows

Study 1: McCoy et al. – Journal of Pharmacology and Experimental Therapeutics (2013) Design: Preclinical study evaluating metabolically stabilized angiotensin IV analogs, including Dihexa, as procognitive and antidementia agents. Rats received scopolamine to induce cognitive deficits and were tested using the Morris water maze. Dihexa was administered both orally (2 mg/kg) and via intravenous injection, and cognitive performance was measured over 8 days of training.

Results: Oral Dihexa (2 mg/kg) reversed scopolamine-induced cognitive deficits by day 7, with treated animals performing no differently from healthy controls. The study confirmed that Dihexa crosses the blood-brain barrier when administered orally. In neurotrophic activity assays, Dihexa was described as seven orders of magnitude more potent than BDNF for promoting new neuronal connections. Significance: Established Dihexa as a potent procognitive/antidementia agent with oral bioavailability and blood-brain barrier penetration—overcoming the major pharmacokinetic limitations of its parent compound angiotensin IV.

Study 2: Benoist et al. – Journal of Pharmacology and Experimental Therapeutics (2014) Design: Mechanistic study investigating the molecular basis of Dihexa’s procognitive and synaptogenic effects. Researchers used binding assays, c-Met phosphorylation assays, cell scattering assays, hippocampal neuron cultures for spine counting, and in vivo Morris water maze testing with intracerebroventricular delivery of an HGF antagonist (“Hinge”). Results: Dihexa bound to HGF with high affinity (Kd = 65 picomolar). Both Dihexa and its parent compound Nle¹-AngIV induced c-Met phosphorylation in the presence of subthreshold concentrations of HGF and augmented HGF-dependent cell scattering. Dihexa and HGF acted synergistically to increase hippocampal neuronal spinogenesis. Intracerebroventricular delivery of the HGF antagonist Hinge completely blocked the procognitive effects of orally administered Dihexa. Significance: Definitively established that Dihexa’s procognitive and synaptogenic effects are entirely dependent on the HGF/c-Met system. Also demonstrated that the HGF/c-Met system is primarily engaged during deficit states rather than normal cognitive function.

Study 3: Wright and Harding – Journal of Alzheimer’s Disease (2015) Design: Comprehensive review summarizing the scientific rationale for targeting the brain HGF/c-Met receptor system as a treatment for Alzheimer’s disease, with detailed analysis of Dihexa’s mechanism and preclinical data. Results: The review established that c-Met receptor activation stimulates mitogenesis, motogenesis, morphogenesis, stem cell differentiation, neurogenesis, and neuroprotection across a wide range of cell types including neurons. Dihexa was confirmed to induce dendritic arborization and synaptogenesis through HGF/c-Met stimulation, offering a mechanistically novel approach to Alzheimer’s treatment. Significance: Positioned the HGF/c-Met system as a validated therapeutic target for neurodegenerative disease and established Dihexa as the leading small-molecule compound for engaging this pathway.

Study 4: Benoist et al. – Journal of Pharmacology and Experimental Therapeutics (2011) Design: Earlier preclinical study evaluating C-terminal truncated Nle¹-angiotensin IV analogs (including precursors to Dihexa) for their ability to facilitate hippocampal synaptogenesis and improve spatial memory in rat models. Results: The analogs facilitated hippocampal synaptogenesis and improved spatial memory performance. The study provided foundational evidence for the structure-activity relationships that guided the development of Dihexa as the optimized analog. Significance: Provided the preclinical groundwork demonstrating that angiotensin IV-derived analogs could promote synaptogenesis and cognitive enhancement, directly leading to the development and optimization of Dihexa.

Study 5: Fosgonimeton (ATH-1017) Clinical Trials – Athira Pharma (2022– 2024) Design: Series of Phase 2 and Phase 2/3 clinical trials evaluating fosgonimeton, a phosphate prodrug of Dihexa, in patients with mild-to-moderate Alzheimer’s disease, Parkinson’s disease dementia, and dementia with Lewy bodies. Fosgonimeton was administered subcutaneously and converts to Dihexa-like active metabolites in the body. Results: The ACT-AD trial (2022) showed cognitive improvement on ADAS-Cog11 in patients not on acetylcholinesterase inhibitors. The SHAPE trial (2023) showed significant improvement at the 40 mg dose for Parkinson’s disease dementia. The LIFT-AD trial (2024) did not meet its primary endpoint but showed biomarker improvements. Safety data across all trials showed no serious adverse events related to the drug. Significance: Provided the first human clinical data supporting HGF/c-Met pathway modulation for neurodegenerative disease. While the LIFT-AD trial failure led to discontinuation of fosgonimeton development, the positive signals in specific patient subgroups (ACT-AD, SHAPE) suggest the HGF/c-Met pathway remains a viable therapeutic target.

Dosing Protocol

Important: Dihexa is not FDA-approved for any indication and remains a research chemical. Optimal dosing protocols have not been established through controlled human clinical trials. The following information is derived from preclinical research data, fosgonimeton clinical trials, and community experience. Any use should be under the supervision of a qualified healthcare provider.

Bioavailability and Delivery Considerations

While Dihexa has demonstrated oral activity in animal models, most research interest centers on injectable or transdermal delivery, which avoids digestive degradation, bypasses first-pass liver metabolism, and produces more consistent systemic exposure. This difference explains why injectable research doses are measured in micrograms to low milligrams, while oral protocols require significantly higher amounts.

Transdermal Application

Protocol Dose Notes Low Dose 1–5 mg once daily Minimum effective dose; recommended starting point Standard 8–15 mg once daily Most commonly referenced dose range Higher Dose 20–30 mg once daily For non-responders; use with caution Cycling 10–15 mg, 5 on/2 off 5 days on, 2 days off to prevent tolerance accumulation

Oral Administration

Protocol Dose Notes Standard 10–20 mg once daily 2- to 4-week initial evaluation period Higher 25–45 mg once daily Higher doses needed due to first-pass metabolism Maintenance 5–10 mg once daily For longer-term, lower-intensity support

Dosing Considerations

with daily dosing. Steady-state levels take approximately 6–8 weeks to achieve. Start low and allow adequate time before dose escalation.

engaged in learning, recovery, or rehabilitation. Passive use without cognitive engagement may yield limited results.

(2–8 weeks), conservative dosing, and avoidance of continuous indefinite use.

stimulation, cycling protocols (5 days on/2 days off, or 4 weeks on/2–4 weeks off) are commonly referenced.

Side Effects

Common Side Effects (Anecdotal Reports) Side Effect Frequency Notes Headache Occasional Typically mild and transient

Fatigue or sleep changes Occasional May include changes in sleep patterns or daytime energy Vivid or altered dreams Occasional Likely related to enhanced synaptic activity during sleep Injection site pain/irritation Common (injectable) Applies to subcutaneous formulations Skin irritation Common (transdermal) At application site; rotate sites to minimize

Fosgonimeton Clinical Trial Safety Data

Safety data from the fosgonimeton (ATH-1017) Phase 2 clinical trials provide the most relevant human safety information for HGF/c-Met pathway modulation. Across the ACT-AD, SHAPE, and LIFT-AD trials, fosgonimeton was generally well tolerated with no serious adverse events attributed to the drug. This provides some reassurance regarding short-term safety of HGF/c-Met pathway engagement in humans, although fosgonimeton is a prodrug formulation with different pharmacokinetic properties than Dihexa itself.

Theoretical Concerns: c-Met as an Oncogene The most significant theoretical concern with Dihexa is that c-Met is a known oncogene. In cancer cells, HGF and c-Met are often overexpressed, and this overexpression correlates with tumorigenesis, metastasis, and poorer prognosis. While short-term preclinical studies have shown no neoplastic induction, and clinical trial data from fosgonimeton showed no cancer- related adverse events, no studies have tested the long-term safety of Dihexa treatment including its potential effects on tumorigenesis and cancer progression. This concern warrants serious consideration, particularly for extended use.

Contraindications and Precautions

Do Not Use If You Have:

tumor growth, metastasis, and angiogenesis. Individuals with active malignancies or a history of cancer should not use Dihexa.

unknown.

unpredictable. Dihexa should not be used by children or adolescents.

psychiatric disorders. Enhanced neuroplasticity in an unstable neurological environment could have unpredictable effects. Use with Caution:

respond to injury and deficit states. The effects of chronic stimulation of this pathway in healthy individuals are unknown.

with conservative dosing are recommended.

characterized. Disclose all medications to your healthcare provider.

angiogenesis, which may theoretically interact with coagulation pathways.

Dihexa vs. Other Cognitive Compounds

Compound Mechanism BBB Crossing Half-Life Status Dihexa HGF/c-Met Excellent 12–13 days Research activation; chemical synaptogenesis Fosgonimeton HGF/c-Met Excellent Similar to Discontinued (prodrug of Dihexa (Phase 2/3)

Dihexa-like

compound) Semax BDNF-like Good Minutes Approved in effects; ACTH (intranasal) Russia analog P21 Neurotrophic; Moderate Hours Research (Cerebrolysin) CNTF-related chemical NSI-189 Hippocampal Good Hours Phase 2 neurogenesis (depression) Noopept Neurotransmitter Good Minutes to hours Approved in modulation; Russia neuroprotection

Dihexa occupies a unique position among cognitive compounds due to its structural mechanism of action (synaptogenesis via HGF/c-Met) rather than neurotransmitter modulation, its exceptional potency relative to BDNF, and its remarkably long half-life. While compounds like Semax, Noopept, and NSI-189 require frequent dosing due to short half-lives, Dihexa’s effects accumulate and persist, requiring fundamentally different dosing strategies.

Success Tips

Start Low and Go Slow

Begin with the minimal effective dose (1–5 mg transdermal or 5–10 mg oral). Allow 1 to 2 weeks before considering dose escalation. Due to the 12- to 13-day half-life, effects build over time through accumulation, and more is not necessarily better. Patience during the initial period is essential.

Active Cognitive Engagement Is Required

Dihexa appears to work best when combined with active cognitive demand. The HGF/c-Met system is primarily engaged during conditions of neural challenge or repair, not passive stimulation. Maximize benefits by pairing Dihexa use with learning new skills (languages, instruments, technical subjects), cognitively demanding work, creative activities and problem- solving, and physical exercise (which independently supports neuroplasticity).

Use Short Research Windows

Given the lack of long-term safety data and theoretical concerns about chronic c-Met activation, responsible use involves short research windows (2–8 weeks), conservative dosing, cycling protocols with adequate off periods, and careful consideration before use in healthy, uninjured brains.

Track Cognitive Metrics

Because Dihexa’s effects are subtle and cumulative rather than immediately perceptible like stimulant nootropics, tracking cognitive metrics over time (memory tests, learning speed, task performance) can help assess response more objectively than subjective impressions alone.

Storage and Handling

term storage (days to weeks). For long-term storage (months to years), store at −20°C (−4°F).

timeframe specified by the supplier.

heat, and moisture. Keep in the original container.

Legal Status

United States: Dihexa is not FDA-approved for any medical condition. It is classified as a research chemical and is not scheduled as a controlled substance. Dihexa is legal to possess for research purposes but cannot be legally sold for human consumption.

International: Regulations vary by country. Dihexa is generally available through research chemical suppliers in most jurisdictions, but users should verify the legal status in their specific region before purchasing. WADA Status: Dihexa is not specifically listed on the World Anti-Doping Agency prohibited substances list. However, athletes should verify current prohibited substance lists, as novel compounds may fall under catch-all categories for unapproved substances.

Product Source

Dihexa is available as a research compound in oral form through www.Biolongevitylabs.store (BioMind: containing Dihexa 10 mg + J-147 10 mg + Noopept 10 mg) When sourcing research- grade Dihexa, ensure the supplier provides third-party testing, certificates of analysis (COA), and proper documentation of purity. Always verify the legitimacy and quality standards of any research compound supplier.

Frequently Asked Questions

What is the difference between Dihexa and fosgonimeton? Fosgonimeton (ATH-1017) is a phosphate prodrug formulation of a Dihexa-related compound developed by Athira Pharma for clinical trials. It converts to active metabolites in the body and was designed for improved pharmacokinetics and subcutaneous administration. Development was discontinued in 2024 after the Phase 2/3 LIFT-AD trial failed to meet its primary endpoint, although positive signals were observed in earlier trials (ACT-AD, SHAPE). Will Dihexa make me smarter? Dihexa is not a “limitless pill.” It works by promoting the formation of new neural connections through the HGF/c-Met pathway and may help with cognitive recovery from deficits, learning new skills more efficiently, or maintaining cognitive function. Effects are highly individual and require active cognitive engagement to manifest. It is best understood as a cognitive repair compound, not a general intelligence enhancer. How long does it take to work? Due to Dihexa’s 12- to 13-day half-life, effects accumulate over time. Some users report subtle improvements within a few days, while others require 1 to 2 weeks. The full therapeutic effect may take several weeks as synaptic connections are formed and strengthened. This is fundamentally different from stimulant-based nootropics that produce immediate but transient effects.

Is Dihexa safe?

Short-term safety appears favorable based on preclinical studies and fosgonimeton clinical trials, which showed no serious adverse events. However, long-term human safety data does not exist. The primary theoretical concern is c-Met receptor activation, as c-Met is a known oncogene. Short-term studies have shown no cancer risk, but the long-term implications of chronic HGF/c- Met stimulation are unknown. Can Dihexa be taken orally? Yes. Dihexa demonstrated oral bioavailability in animal models, with oral doses (2 mg/kg in rats) effectively reversing cognitive deficits. However, oral administration requires higher doses than injectable or transdermal routes due to first-pass liver metabolism and digestive degradation. Most researchers consider injectable or transdermal delivery to produce more consistent and efficient systemic exposure. Should I use Dihexa if my brain is healthy? This is an area of uncertainty. Research suggests the HGF/c-Met system is primarily engaged during conditions of injury or deficit rather than normal cognitive function. The effects of chronically stimulating this pathway in healthy individuals are unknown. Conservative researchers recommend caution regarding use in healthy, uninjured brains and emphasize that Dihexa is best suited for cognitive repair and recovery scenarios.

References

1. McCoy AT, Benoist CC, Wright JW, et al. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. J Pharmacol Exp Ther. 2013;344(1):141–154. 2. Benoist CC, Kawas LH, Zhu M, et al. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c- Met system. J Pharmacol Exp Ther. 2014;351(2):390–402. 3. Wright JW, Harding JW. The brain hepatocyte growth factor/c-Met receptor system: a new target for the treatment of Alzheimer’s disease. J Alzheimers Dis. 2015;45(4):985–1000. 4. Benoist CC, Wright JW, Zhu M, Appleyard SM, Wayman GA, Harding JW. Facilitation of hippocampal synaptogenesis and spatial memory by C-terminal truncated Nle¹-angiotensin IV analogs. J Pharmacol Exp Ther. 2011;339(1):35–44. https://pubmed.ncbi.nlm.nih.gov/21719467/ 5. Moebius HJ, Church KJ. Fosgonimeton: a small molecule positive modulator of hepatocyte growth factor/mesenchymal-epithelial transition factor signaling for Alzheimer’s disease. Expert Opin Investig Drugs. 2023;32(3):181–188. https://pubmed.ncbi.nlm.nih.gov/36803207/ 6. Athira Pharma. Topline results from ACT-AD Phase 2 proof of concept study of fosgonimeton in mild-to-moderate Alzheimer’s disease. Press release. June 22, 2022.

7. Athira Pharma. Results from SHAPE Phase 2 clinical trial of fosgonimeton for Parkinson’s disease dementia and dementia with Lewy bodies. Press release. December 12, 2023. 8. Athira Pharma. Topline results from Phase 2/3 LIFT-AD trial of fosgonimeton. Press release. October 2024. 9. Alzheimer’s Drug Discovery Foundation. Dihexa. Cognitive Vitality Reports. Updated August 13, 2021. https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Dihexa_1.pdf

Property Support

Our Property Support services are designed to help homeowners, property managers, and businesses maintain safe, clean, and well-functioning properties year-round.

Get In Touch